FEATURED VIDEO

INVESTING IN HEALTHCARE

Coming soon...

Talk Show: Building an Investor Base in Europe (0:53)

MEMBER MANAGEMENT PROFILES

Endocare

Developing Cryoblation technology for minimally invasive treatment of prostate and renal cancer, tumors in the kidneys, lungs, and liver. (5:58)

Clearant

Developing sterilization processes to reduce pathogens risk in implementation of human tissue. (8:42)

Synthemed

Anti-adhesion products to reduce the formation of adhesions (scar tissue) following a range of surgical procedures. (6:24)

Symphony

Treating atrial fibrillation with biologic therapies. (6:40)

ISTO

Regenerating and restoring damaged cartilage and bone. (5:05)

NeoChord

Minimally Invasive Alternative for Mitral Valve Regurgitation Repair (5:46)

Arbios Systems to Begin Pivotal Trials for its SEPET Liver Assist Device

Liver and biliary diseases affect 25 million Americans, whose annual healthcare costs exceed $10 billion. Unfortunately, there are no direct treatments available for liver failure and patients must receive a liver transplant or endure prolonged hospitalization with significant mortality. Arbios Systems is developing products to replace liver function or provide support pending liver regeneration or […]

Squeaking Stryker Hip Implant

A story in the New York Times today sheds light on an increasingly common occurrence: squeaking hips.

A study in the Journal of Arthroplasty found that 7% of patients who received ceramic hips from 2003 to 2005 developed squeaks. No squeaks were found in a control group of 48 patients who received metal on plastic replacements.
Doctors […]

[Video Profile] Interview with Jim Dayton, Executive VP and Managing Director of Safeguard Scientifics

Safeguard Scientifics is a holding company that invests in growth-stage life sciences and technology. In addition to capital, Safeguard provides strategic, operational and management resources to its portfolio companies. As a public company (NYSE: SFE), Safeguard is not subject to the limits of the three-to-seven-year fund raising cycles found in venture capital or buyout firms. […]

NuVasive to Acquire Osteocel Biologics Business from Osiris Therapeutics

The $200 million NuVasive raised in a March offering may soon be put to good use. The company announced yesterday the pending acquisition of the Osteocel biologics business from Osiris Therapeutics.
Osteocel is a bone matrix product containing stem cells. Like an autograft, it is biologically active and provides the beneficial properties of osteoconduction, osteoinduction, and […]

Myriad Goes Direct (Again)

Myriad Genetic Laboratories develops and markets proprietary predictive and personalized medicine products. This includes the poorly branded BRACAnalysis, to assess a woman’s risk of developing breast or ovarian cancer based on detection of mutations in the BRCA1 and BRCA2 genes. The test is reimbursed by most insurance carriers and is recommended for women with a […]

South Korean FDA Approves Cynosure’s Accolade Workstation for Pigmented Lesions

Although freckles occur most often in light skinned individuals with blond hair and blue eyes, freckles are also common among Asians, including Koreans. While they can look good, I’ve learned in my 25 years to never get between a woman and her happiness.
Cynosure, based in Westford, MA, offers an array of laser-based aesthetic treatment systems. […]

BioElectronics Corp. Merits a First Look

Most investors won’t touch a stock trading on the pink sheets with a ten foot medical device. But for the risk-inclined among you, BioElectronics Corp. (BIEL) may warrant a first look.
The company, which has gone largely unnoticed by investors, is trading near its year-long low, despite management initiatives that have already begun to pay off.

Based […]